Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HP-038
- Development stage
- Preclinical
- Lead developer
- Housey Pharma
- Modality
- Small Molecules
01
Overview
HP-038 is a preclinical small molecule activator of Insulin Receptor Substrate 2 (IRS-2) being developed by Housey Pharmaceutical Research Laboratories for the treatment of Type 2 Diabetes. IRS-2 is a critical signaling protein that mediates the metabolic effects of insulin; its activation is intended to enhance insulin sensitivity and improve glucose metabolism. The drug is part of Housey's pipeline focusing on metabolic disorders and is currently in the preclinical stage of development.
Beyond the preview
Go deeper on HP-038.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HP-038.